Extracellular Vesicle-Based mRNA Therapeutics and Vaccines

Abstract

Messenger RNA (mRNA) therapeutics and vaccines have recently gained particular prominence following the COVID-19 epidemic. However, clinical translation of mRNAs is critically dependent on efficient and safe delivery in vivo. Currently, a plethora of mRNA delivery technology platforms (such as lipid nanoparticles) have been developed and have achieved stunning success. Nevertheless, many challenges remain to be overcome, including immunogenicity and toxicities, excessive liver accumulation, limited endosomal escape ability, low tissue bioavailability, poor mucosal immunity, and the need for cold chain storage. In recent years, extracellular vesicles (EVs) have emerged as an attractive mRNA delivery platform due to their favorable properties, such as low immunogenicity, natural capability to deliver RNAs, intrinsic targeting capacity, and the ability to negotiate with physiological barriers. In this review, we discuss the latest efforts to harness EVs for mRNA delivery and elaborate the behind mechanisms, aiming to offering insights into the rational design of effective and safe EV-based mRNA therapeutics and vaccines for biomedical applications. Additionally, we provide an overview of EV biogenesis, composition, cellular internalization, and their superiorities and challenges for mRNA delivery, with special emphasis on the state-of-the-art methodologies for packaging EVs with mRNAs.

Keywords

extracellular vesicles / messenger RNAs / delivery / packaging strategies / vaccines

References

[1] Y. Xiao, Z. Tang, X. Huang, et al., “Emerging mRNA Technologies: Delivery Strategies and Biomedical Applications,” Chemical Society Reviews51 (2022): 3828.

[2] D. E. Murphy, O. G. de Jong, M. J. W. Evers, M. Nurazizah, R. M. Schiffelers, and P. Vader, “Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles,” Nano Letters21 (2021): 1888.

[3] A. D. Springer and S. F. Dowdy, “GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics,” Nucleic Acid Therapeutics28 (2018): 109.

[4] Z. Yang, J. Shi, J. Xie, et al., “Large-Scale Generation of Functional mRNA-Encapsulating Exosomes via Cellular Nanoporation,” Nature Biomedical Engineering4 (2020): 69.

[5] C. Wang, Y. Zhang, and Y. Dong, “Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications,” Accounts of Chemical Research54 (2021): 4283.

[6] Y. Zong, Y. Lin, T. Wei, and Q. Cheng, “Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy,” Advanced Materials35 (2023): e2303261.

[7] E. Kon, N. Ad-El, I. Hazan-Halevy, L. Stotsky-Oterin, and D. Peer, “Targeting Cancer With mRNA–Lipid Nanoparticles: Key Considerations and Future Prospects,” Nature Reviews Clinical Oncology20 (2023): 739.

[8] R. Tenchov, R. Bird, A. E. Curtze, and Q. Zhou, “Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement,” ACS Nano15 (2021):16982.

[9] L. Rui, L. Cong, P. Zhiqing, et al., “Advances of Nanoparticles as Drug Delivery Systems for Disease Diagnosis and Treatment,” Chinese Chemical Letters34 (2023): 107518.

[10] Y. You, Y. Tian, Z. Yang, et al., “Intradermally Delivered mRNA-Encapsulating Extracellular Vesicles for Collagen-Replacement Therapy,” Nature Biomedical Engineering7 (2023): 887.

[11] C. Théry, K. W. Witwer, E. Aikawa, et al., “Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines,” Journal of Extracellular Vesicles7 (2018): 1535750.

[12] G. van Niel, G. D'Angelo, and G. Raposo, “Shedding Light on the Cell Biology of Extracellular Vesicles,” Nature Reviews Molecular Cell Biology19 (2018): 213.

[13] A. Becker, B. K. Thakur, J. M. Weiss, H. S. Kim, H. Peinado, and D. Lyden, “Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis,” Cancer Cell30 (2016): 836.

[14] S. Maacha, A. A. Bhat, L. Jimenez, et al., “Extracellular Vesicles-Mediated Intercellular Communication: Roles in the Tumor Microenvironment and Anti-Cancer Drug Resistance,” Molecular Cancer18 (2019): 55.

[15] G. Raposo and P. D. Stahl, “Extracellular Vesicles: A New Communication Paradigm?,” Nature Reviews Molecular Cell Biology20 (2019): 509.

[16] G. van Niel, D. R. F. Carter, A. Clayton, D. W. Lambert, and G. R. P. Vader, “Challenges and Directions in Studying Cell-Cell Communication by Extracellular Vesicles,” Nature Reviews Molecular Cell Biology23 (2022): 369.

[17] P. Vader, E. A. Mol, G. Pasterkamp, and R. M. Schiffelers, “Extracellular Vesicles for Drug Delivery,” Advanced Drug Delivery Reviews106 (2016): 148.

[18] D. Yuan, Y. Zhao, W. A. Banks, et al., “Macrophage Exosomes as Natural Nanocarriers for Protein Delivery to Inflamed Brain,” Biomaterials142 (2017): 1.

[19] D. E. Murphy, O. G. de Jong, M. Brouwer, et al., “Extracellular Vesicle-Based Therapeutics: Natural Versus Engineered Targeting and Trafficking,” Experimental & Molecular Medicine51 (2019): 32.

[20] W. Tianqi, F. Yanan, S. Shengjie, et al., “Exosome-Based Drug Delivery Systems in Cancer Therapy,” Chinese Chemical Letters34 (2023): 107508.

[21] K. D. Popowski, A. Moatti, G. Scull, et al., “Inhalable Dry Powder mRNA Vaccines Based on Extracellular Vesicles,” Matter5 (2022): 2960.

[22] C. Aslan, S. H. Kiaie, N. M. Zolbanin, et al., “Exosomes for mRNA Delivery: A Novel Biotherapeutic Strategy With Hurdles and Hope,” BMC Biotechnology21 (2021): 20.

[23] Q. Zhang, M. Wang, C. Han, et al., “Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice” Vaccines11 (2023): 673.

[24] X. Huang, A. Li, P. Xu, et al., “Current and Prospective Strategies for Advancing the Targeted Delivery of CRISPR/Cas System Via Extracellular Vesicles,” Journal of Nanobiotechnology21 (2023): 184.

[25] S. J. Tsai, C. Guo, A. Sedgwick, et al., “Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination,” BioRxiv10 (2021): 371419.

[26] W. M. Usman, T. C. Pham, Y. Y. Kwok, et al., “Efficient RNA Drug Delivery Using Red Blood Cell Extracellular Vesicles,” Nature Communications9 (2018): 2359.

[27] E. P. Erkan, D. Senfter, S. Madlener, et al., “Extracellular Vesicle-Mediated Suicide mRNA/Protein Delivery Inhibits Glioblastoma Tumor Growth In Vivo,” Cancer Gene Therapy24 (2017): 38.

[28] J. H. Wang, A. V. Forterre, J. Zhao, et al., “Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation,” Molecular Cancer Therapeutics17 (2018): 1133.

[29] H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-Mediated Transfer of mRNAs and microRNAs is a Novel Mechanism of Genetic Exchange Between Cells,” Nature Cell Biology9 (2007): 654.

[30] L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M. J. A. Wood, “Delivery of siRNA to the Mouse Brain by Systemic Injection of Targeted Exosomes,” Nature Biotechnology29 (2011): 341.

[31] Y. Xing, F. Zhang, P. Ji, et al., “Efficient Delivery of GSDMD-N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy,” Small19 (2023): e2204031.

[32] V. Sharma and C. D. Mukhopadhyay, “Exosome as Drug Delivery System: Current Advancements,” Extracellular Vesicle3 (2024): 10032.

[33] T. Eileen, B. Nathan, and C. Y. Phillip, “Current challenges surrounding exosome treatments,” Extracellular Vesicle2 (2023): 100023.

[34] W. Wang, N. Zhu, T. Yan, et al., “The Crosstalk: Exosomes and Lipid Metabolism,” Cell Communication and Signaling18 (2020): 119.

[35] M. Cully, “Exosome-Based Candidates Move Into the Clinic,” Nature Reviews Drug Discovery20 (2021): 6.

[36] L. Mashouri, H. Yousefi, A. R. Aref, A. M. Ahadi, F. Molaei, and S. K. Alahari, “Exosomes: Composition, Biogenesis, and Mechanisms in Cancer Metastasis and Drug Resistance,” Molecular Cancer18 (2019): 75.

[37] V. P. Chavda, G. Luo, R. Bezbaruah, et al., “Unveiling the Promise: Exosomes as Game‑Changers in Anti‑Infective Therapy,” Exploration4 (2024): 20230139.

[38] M. Mathieu, L. Martin-Jaular, G. Lavieu, and C. Théry, “Specificities of Secretion and Uptake of Exosomes and Other Extracellular Vesicles for Cell-to-Cell Communication,” Nature Cell Biology21 (2019): 9.

[39] N. P. Hessvik and A. Llorente, “Current Knowledge on Exosome Biogenesis and Release,” Cellular and Molecular Life Sciences75 (2018): 193.

[40] J. Huotari and A. Helenius, “Endosome Maturation,” Embo Journal30 (2011): 3481.

[41] I. J. McGough and J. P. Vincent, “Exosomes in Developmental Signalling,” Development143 (2016): 2482.

[42] A. C. Dixson, T. R. Dawson, D. Di Vizio, and A. M. Weaver, “Context-Specific Regulation of Extracellular Vesicle Biogenesis and Cargo Selection,” Nature Reviews Molecular Cell Biology24 (2023): 454.

[43] T. Wollert, C. Wunder, J. Lippincott-Schwartz, and J. H. Hurley, “Membrane Scission by the ESCRT-III Complex,” Nature458 (2009): 172.

[44] M. J. Kennedy and M. D. Ehlers, “Mechanisms and Function of Dendritic Exocytosis,” Neuron69 (2011): 856.

[45] J. Meldolesi, “Exosomes and Ectosomes in Intercellular Communication,” Current Biology28 (2018): R435.

[46] M. J. Shurtleff, J. Yao, Y. Qin, et al., “Broad Role for YBX1 in Defining the Small Noncoding RNA Composition of Exosomes,” PNAS114 (2017): E8987.

[47] C. Villarroya-Beltri, C. Gutiérrez-Vázquez, F. Sánchez-Cabo, et al., “Sumoylated hnRNPA2B1 Controls the Sorting of miRNAs Into Exosomes Through Binding to Specific Motifs,” Nature Communications4 (2013): 2980.

[48] S. Dong, X. Liu, Y. Bi, et al., “Adaptive Design of mRNA-Loaded Extracellular Vesicles for Targeted Immunotherapy of Cancer,” Nature Communications14 (2023): 6610.

[49] L. A. Mulcahy, R. C. Pink, and D. R. Carter, “Routes and mechanisms of extracellular vesicle uptake,” Journal of Extracellular Vesicles3 (2014): 24641.

[50] K. J. McKelvey, K. L. Powell, A. W. Ashton, J. M. Morris, and S. A. McCracken, “Exosomes: Mechanisms of Uptake,” Journal of Circulating Biomarkers4 (2015): 7.

[51] X. P. Lin, J. D. Mintern, and P. A. Gleeson, “Macropinocytosis in Different Cell Types: Similarities and Differences,” Membranes (Basel)10 (2020): 177.

[52] C. Williams, R. Pazos, F. Royo, et al., “Assessing the Role of Surface Glycans of Extracellular Vesicles on Cellular Uptake,” Scientific Reports9 (2019): 11920.

[53] S. Sato, S. Vasaikar, A. Eskaros, et al., “EPHB2 Carried on Small Extracellular Vesicles Induces Tumor Angiogenesis via Activation of Ephrin Reverse Signaling,” JCI Insight4 (2019): e132447.

[54] S. Kanno, S. Hirano, T. Sakamoto, et al., “Scavenger Receptor MARCO Contributes to Cellular Internalization of Exosomes by Dynamin-Dependent Endocytosis and Macropinocytosis,” Scientific Reports10 (2020): 21795.

[55] C. He, S. Zheng, Y. Luo, and B. Wang, “Exosome Theranostics: Biology and Translational Medicine,” Theranostics8 (2018): 237.

[56] A. Clayton, A. Turkes, S. Dewitt, R. Steadman, M. D. Mason, and M. B. Hallett, “Adhesion and Signaling by B Cell-Derived Exosomes: The Role of Integrins,” Faseb Journal18 (2004): 977.

[57] B. Yu, H. W. Kim, M. Gong, et al., “Exosomes Secreted From GATA-4 Overexpressing Mesenchymal Stem Cells Serve as a Reservoir of Anti-Apoptotic microRNAs for Cardioprotection,” International Journal of Cardiology182 (2015): 349.

[58] S. El-Andaloussi, Y. Lee, S. Lakhal-Littleton, et al., “Exosome-Mediated Delivery of siRNA In Vitro and In Vivo,” Nature Protocols7 (2012): 2112.

[59] A. Hoshino, B. Costa-Silva, T. Shen, et al., “Tumour Exosome Integrins Determine Organotropic Metastasis,” Nature527 (2015): 329.

[60] A. K. Agrawal, F. Aqil, J. Jeyabalan, et al., “Milk-Derived Exosomes for Oral Delivery of Paclitaxel,” Nanomedicine13 (2017): 1627.

[61] M. A. Morse, J. Garst, T. Osada, et al., “A Phase I Study of Dexosome Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer,” Journal of Translational Medicine3 (2005): 9.

[62] R. D. Kirian, D. Steinman, C. M. Jewell, and H. C. Zierden, “Extracellular Vesicles as Carriers of mRNA: Opportunities and Challenges in Diagnosis and Treatment,” Theranostics14 (2024): 2265.

[63] Y. Liang, L. Duan, J. Lu, and J. Xia, “Engineering Exosomes for Targeted Drug Delivery,” Theranostics11 (2021): 3183.

[64] Y. Tian, S. Li, J. Song, et al., “A Doxorubicin Delivery Platform Using Engineered Natural Membrane Vesicle Exosomes for Targeted Tumor Therapy,” Biomaterials35 (2014): 2383.

[65] G. Jia, Y. Han, Y. An, et al., “NRP-1 Targeted and Cargo-Loaded Exosomes Facilitate Simultaneous Imaging and Therapy of Glioma In Vitro and In Vivo,” Biomaterials178 (2018): 302.

[66] T. Tian, H. X. Zhang, C. P. He, et al., “Surface Functionalized Exosomes as Targeted Drug Delivery Vehicles for Cerebral Ischemia Therapy,” Biomaterials150 (2018): 137.

[67] X. Huang, N. Kong, X. Zhang, Y. Cao, R. Langer, and W. Tao, “The Landscape of mRNA Nanomedicine,” Nature Medicine28 (2022): 2273.

[68] U. Sahin, K. Karikó, and Ö. Türeci, “mRNA-Based Therapeutics — Developing a New Class of Drugs,” Nature Reviews Drug Discovery13 (2014): 759.

[69] S. J. Tsai, N. A. Atai, M. Cacciottolo, et al., “Exosome-mediated mRNA Delivery In Vivo is Safe and can be Used to Induce SARA-CoV-2 Immunity,” Journal of Biological Chemistry297, no. 5 (2021): 101266.

[70] L. Kordelas, V. Rebmann, A. K. Ludwig, et al., “MSC-Derived Exosomes: A Novel Tool to Treat Therapy-Refractory Graft-Versus-Host Disease,” Leukemia28 (2014): 970.

[71] I. Parolini, C. Federici, C. Raggi, et al., “Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells,” Journal of Biological Chemistry284 (2009): 34211.

[72] L. Cheng, R. A. Sharples, B. J. Scicluna, and A. F. Hill, “Exosomes Provide a Protective and Enriched Source of miRNA for Biomarker Profiling Compared to Intracellular and Cell-Free Blood,” Journal of Extracellular Vesicles3 (2014): 23743.

[73] K. D. Popowski, B. López de Juan Abad, A. George, et al., “Inhalable Exosomes Outperform Liposomes as mRNA and Protein Drug Carriers to the Lung,” Extracellular Vesicle1 (2022): 100002.

[74] C. L. Chiang, Y. Ma, Y. Chin Hou, et al., “Dual Targeted Extracellular Vesicles Regulate Oncogenic Genes in Advanced Pancreatic Cancer,” Nature Communication14 (2023): 6692.

[75] G. Ronzitti, D. A. Gross, and F. Mingozzi, “Human Immune Responses to Adeno-Associated Virus (AAV) Vectors,” Frontiers in Immunology11 (2020): 670.

[76] C. E. Thomas, A. Ehrhardt, and M. A. Kay, “Progress and problems With the Use of Viral Vectors for Gene Therapy,” Nature Reviews Genetics4 (2003): 346.

[77] L. S. Mbatha, F. Maiyo, A. Daniels, and M. Singh, “Dendrimer-Coated Gold Nanoparticles for Efficient Folate-Targeted mRNA Delivery In Vitro,” Pharmaceutics13 (2021): 900.

[78] Y. Liu, C. Zhao, A. Sabirsh, et al., “A Novel Graphene Quantum Dot-Based mRNA Delivery Platform,” ChemistryOpen10 (2021): 666.

[79] Z. Sharifnia, M. Bandehpour, H. Hamishehkar, N. Mosaffa, B. Kazemi, and N. Zarghami, “In-Vitro Transcribed mRNA Delivery Using PLGA/PEI Nanoparticles Into Human Monocyte-Derived Dendritic Cells,” Iranian Journal of Pharmaceutical Sciences18 (2019): 1659.

[80] W. Yang, P. Chen, E. Boonstra, T. Hong, and H. Cabral, “Polymeric Micelles With pH-Responsive Cross-Linked Core Enhance In Vivo mRNA Delivery,” Pharmaceutics14 (2022): 1205.

[81] H. Y. Choi, T. J. Lee, G. M. Yang, et al., “Efficient mRNA Delivery With Graphene Oxide-Polyethylenimine for GENEration of Footprint-Free Human Induced Pluripotent Stem Cells,” Journal of Controlled Release235 (2016): 222.

[82] Y. Li, X. Ma, Y. Yue, et al., “Rapid Surface Display of mRNA Antigens by Bacteria-Derived Outer Membrane Vesicles for a Personalized Tumor Vaccine,” Advanced Materials34 (2022): e2109984.

[83] H. Kang, Y. Bae, Y. Kwon, S. Kim, and J. Park, “Extracellular Vesicles Generated Using Bioreactors and their Therapeutic Effect on the Acute Kidney Injury Model,” Advanced Healthcare Materials11 (2022): e2101606.

[84] X. Yuan, L. Sun, R. Jeske, et al., “Engineering Extracellular Vesicles by Three-Dimensional Dynamic Culture of Human Mesenchymal Stem Cells,” Journal of Extracellular Vesicles11 (2022): e12235.

[85] L. Song, S. Tang, X. Han, et al., “KIBRA Controls Exosome Secretion Via Inhibiting the Proteasomal Degradation of Rab27a,” Nature Communications10 (2019): 1639.

[86] F. Momen-Heravi, S. Bala, T. Bukong, and G. Szabo, “Exosome-Mediated Delivery of Functionally Active miRNA-155 Inhibitor to Macrophages,” Nanomedicine10 (2014): 1517.

[87] K. O'Brien, K. Breyne, S. Ughetto, L. C. Laurent, and X. O. Breakefield, “RNA Delivery by Extracellular Vesicles in Mammalian Cells and Its Applications,” Nature Reviews Molecular Cell Biology21 (2020): 585.

[88] R. Kojima, D. Bojar, G. Rizzi, et al., “Designer Exosomes Produced by Implanted Cells Intracerebrally Deliver Therapeutic Cargo for Parkinson's Disease Treatment,” Nature Communications9 (2018): 1305.

[89] Z. Li, Z. Liu, J. Wu, and B. Li, “Cell-Derived Vesicles for mRNA Delivery,” Pharmaceutics14 (2022): 2699.

[90] S. Deville, P. Berckmans, R. Van Hoof, I. Lambrichts, A. Salvati, and I. Nelissen, “Comparison of Extracellular Vesicle Isolation and Storage Methods Using High-Sensitivity Flow Cytometry,” PLoS ONE16 (2021): e0245835.

[91] C. Chiang, Y. Ma, Y. Hou, et al., “Dual Targeted Extracellular Vesicles Regulate Oncogenic Genes in Advanced Pancreatic Cancer,” Nature Communications14 (2023): 6692.

[92] H. Parhiz, E. N. Atochina-Vasserman, and D. Weissman, “mRNA-based therapeutics: Looking Beyond COVID-19 Vaccines,” Lancet403 (2024): 1192.

[93] T. Bu, Z. Li, Y. Hou, et al., “Exosome-Mediated Delivery of Inflammation-Responsive Il-10 mRNA for Controlled Atherosclerosis Treatment,” Theranostics11 (2021): 9988.

[94] E. P. Erkan, N. Saydam, C. C. Chen, and O. Saydam, “Extracellular Vesicles as Carriers of Suicide mRNA and/or Protein in Cancer Therapy,” Methods in Molecular Biology1895 (2019): 87.

[95] Z. Li, X. Zhou, M. Wei, et al., “In Vitro and In Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated With miRNA or CRISPR/dCas9,” Nano Letters19 (2019): 19.

[96] S. Zhang, Y. Dong, Y. Wang, et al., “Selective Encapsulation of Therapeutic mRNA in Engineered Extracellular Vesicles by DNA Aptamer,” Nano Letters21 (2021): 8563.

[97] P. Kumar, A. Nagarajan, and P. D. Uchil, “Electroporation,” Cold Spring Harbor Protocols2019 (2019): 519-525.

[98] S. Tang, A. Salazar-Puerta, J. Richards, et al., “Non-Viral Reprogramming of Human Nucleus Pulposus Cells With FOXF1 via Extracellular Vesicle Delivery: An In Vitro and In Vivo Study,” European Cells & Materials41 (2021): 90.

[99] S. J. Tsai, N. A. Atai, M. Cacciottolo, et al., “Exosome-Mediated Mrna Delivery In Vivo is Safe and can be Used to Induce SARS-CoV-2 Immunity,” Journal of Biological Chemistry297 (2021): 101266.

[100] M. S. Kim, M. J. Haney, Y. Zhao, et al., “Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells,” Nanomedicine12 (2016): 655.

[101] W. Sun, C. Xing, L. Zhao, P. Zhao, G. Yang, and L. Yuan, “Ultrasound Assisted Exosomal Delivery of Tissue Responsive mRNA for Enhanced Efficacy and Minimized Off-Target Effects,” Molecular Therapy Nucleic Acids20 (2020): 558.

[102] Y. Zhan, Y. Song, W. Qiao, et al., “Focused Ultrasound Combined With miR-1208-Equipped Exosomes Inhibits Malignant Progression of Glioma,” British Journal of Cancer129 (2023): 1083.

[103] S. Wu, J. Yun, W. Tang, et al., “Therapeutic m6A Eraser ALKBH5 mRNA-Loaded Exosome-Liposome Hybrid Nanoparticles Inhinit Progression of Colorectal Cancer in Preclinical Tumor Models,” ACS Nano17 (2023): 11838-11854.

[104] F. Zhang, J. Guo, Z. Zhang, et al., “Application of Engineered Extracellular Vesicles for Targeted Tumor Therapy,” Journal of Biomedical Science14 (2022): 29.

[105] Z. Li, Z. Liu, J. Wu, and B. A.-O. Li, “Opportunities and Challenges in the Delivery of mRNA‑Based Vaccines,” Pharmaceutics14, no. 2 (2020): 2699.

[106] D. Bitounis, E. Jacquinet, M. A. Rogers, and M. M. Amiji, “Strategies to Reduce the Risks of mRNA Drug and Vaccine Toxicity,” Nature Reviews Drug Discovery23 (2024): 281.

[107] S. Zou, K. Scarfo, M. H. Nantz, and J. G. Hecker, “Lipid-Mediated Delivery of RNA is More Efficient Than Delivery of DNA in Non-Dividing Cells,” International Journal of Pharmaceutics389 (2010): 232.

[108] A. Wadhwa, A. Aljabbari, A. Lokras, C. Foged, and A. Thakur, “Opportunities and Challenges in the Delivery of mRNA-Based Vaccines,” Pharmaceutics12 (2020): 102.

[109] U. Sahin, E. Derhovanessian, M. Miller, et al., “Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity Against Cancer,” Nature547 (2017): 222.

[110] F. Zhou, L. Huang, S. Li, et al., “From Structural Design to Delivery: MRNA Therapeutics for Cancer Immunotherapy,” Exploration4 (2024): 20210146.

[111] B. Bozkurt, I. Kamat, and P. J. Hotez, “Myocarditis With COVID-19 mRNA Vaccines,” Circulation144 (2021): 471.

[112] A. J. Barbier, A. Y. Jiang, P. Zhang, R. Wooster, and D. G. Anderson, “The Clinical Progress of mRNA Vaccines and Immunotherapies,” Nature Biotechnology40 (2022): 840.

[113] L. Miao, Y. Zhang, and L. Huang, “mRNA Vaccine for Cancer Immunotherapy,” Molecular Cancer20 (2021): 41.

[114] R. Scott McIvor, “Therapeutic Delivery of mRNA: The Medium is the Message,” Molecular Therapy19 (2011): 822.

[115] M. Li, Y. Li, S. Li, et al., “The Nano Delivery Systems and Applications of mRNA,” European Journal of Medicinal Chemistry227 (2022): 113910.

[116] L. L. Lv, Y. H. Cao, M. M. Pan, et al., “CD2AP mRNA in Urinary Exosome as Biomarker of Kidney Disease,” Clinica Chimica Acta428 (2014): 26.

[117] J. Jiang, J. Mei, Y. Ma, et al., “Tumor Hijacks Macrophages and Microbiota Through Extracellular Vesicles,” Exploration2 (2022): 20210144.

[118] J. D. Beck, D. Reidenbach, N. Salomon, et al., “mRNA Therapeutics in Cancer Immunotherapy,” Molecular Cancer20 (2021): 69.

[119] A. V. Forterre, J. H. Wang, A. Delcayre, et al., “Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 Without General Toxicity,” Molecular Cancer Therapeutics19 (2020): 858.

[120] I. Pérez-Núñez, C. Rozalén, J. Á. Palomeque, et al., “LCOR Mediates Interferon-Independent Tumor Immunogenicity and Responsiveness to Immune-Checkpoint Blockade in Triple-Negative Breast Cancer,” Nature Cancer3 (2022): 355.

[121] A. Yokoi, Y. Yoshioka, Y. Yamamoto, et al., “Malignant Extracellular Vesicles Carrying MMP1 mRNA Facilitate Peritoneal Dissemination in Ovarian Cancer,” Nature Communications8 (2017): 14470.

[122] C. Almeida, A. L. Teixeira, F. Dias, et al., “Extracellular Vesicles Derived-LAT1 mRNA as a Powerful Inducer of Colorectal Cancer Aggressive Phenotype,” Biology (Basel)11 (2022): 145.

[123] M. Liu, S. Hu, N. Yan, K. D. Popowski, and K. Cheng, “Inhalable Extracellular Vesicle Delivery of IL-12 mRNA to Treat Lung Cancer and Promote Systemic Immunity,” Nature Nanotechnology19 (2024): 565-575.

[124] S. Qing, C. Lyu, L. Zhu, et al., “Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy,” Advanced Materials32 (2020): e2002085.

[125] Z. Wang, J. Ding, Y. Xiao, et al., “Serum Extracellular Vesicles With NSD1 and FBXO7 mRNA as Novel Biomarkers for Gastric Cancer,” Clinical Biochemistry120 (2023): 110653.

[126] S. Dong, A. Antony, Y. Wang, B. Kim, and W. Jiang, “EXTH-14. mRNA-Loaded Exosomes for Targeted Glioblastoma Immunotherapy,” Neuro-Oncology25 (2023): v226.

[127] S. Wu, J. Yun, W. Tang, et al., “Therapeutic m 6 A Eraser ALKBH5 mRNA-Loaded Exosome–Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models,” ACS Nano17 (2023): 11838.

[128] R. C. Larson and M. V. Maus, “Recent Advances and Discoveries in the Mechanisms and Functions of CAR T Cells,” Nature Reviews Cancer21 (2021): 145.

[129] K. Si, Z. Dai, Z. Li, et al., “Engineered Exosome-Mediated Messenger RNA and Single-Chain Variable Fragment Delivery for Human Chimeric Antigen Receptor T-cell Engineering,” Cytotherapy25 (2023): 615.

[130] X. Chen, Z. Wan, L. Yang, et al., “Exosomes Derived From Reparative M2-Like Macrophages Prevent Bone Loss in Murine Periodontitis Models via IL-10 mRNA,” Journal of Nanobiotechnology20 (2022): 110.

[131] J. Guo, F. Zhou, Z. Liu, et al., “Exosome-Shuttled Mitochondrial Transcription Factor A mRNA Promotes the Osteogenesis of Dental Pulp Stem Cells Through Mitochondrial Oxidative Phosphorylation Activation,” Cell Proliferation55 (2022): e13324.

[132] P. Wu, B. Zhang, H. Shi, H. Qian, and W. Xu, “MSC-exosome: A Novel Cell-Free Therapy for Cutaneous Regeneration,” Cytotherapy20 (2018): 291.

[133] B. Mi, L. Chen, Y. Xiong, et al., “Saliva Exosomes-Derived UBE2O mRNA Promotes Angiogenesis in Cutaneous Wounds by Targeting SMAD6,” Journal of Nanobiotechnology18 (2020): 68.

[134] Y. Ma, L. Sun, J. Zhang, et al., “Exosomal mRNA for Angiogenic-Osteogenic Coupled Bone Repair,” Advanced Science10 (2023): e2302622.

[135] M. Mitsuhashi, D. D. Taub, D. Kapogiannis, et al., “Aging Enhances Release of Exosomal Cytokine mRNAs by Aβ 1-42 -Stimulated Macrophages,” Faseb Journal27 (2013): 5141.

[136] M. Zazzi, H. Hu, and M. Prosperi, “The Global Burden of HIV-1 Drug Resistance in the Past 20 Years,” PeerJ6 (2018): e4848.

[137] J. R. Nansseu and J. J. Bigna, “Antiretroviral Therapy Related Adverse Effects: Can Sub-Saharan Africa Cope With the New “Test and Treat” Policy of the World Health Organization?,” Infectious Diseases of Poverty6 (2017): 24.

[138] S. Shrivastava, R. M. Ray, L. Holguin, et al., “Exosome-Mediated Stable Epigenetic Repression of HIV-1,” Nature Communications12 (2021): 5541.

[139] Y. G. Zhu, X. M. Feng, J. Abbott, et al., “Human Mesenchymal Stem Cell Microvesicles for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in Mice,” Stem Cells32 (2014): 116.

[140] Y. Guo, Z. Wan, P. Zhao, et al., “Ultrasound Triggered Topical Delivery of Bmp7 mRNA for White Fat Browning Induction via Engineered Smart Exosomes,” Journal of Nanobiotechnology19 (2021): 402.

[141] N. Pardi, M. J. Hogan, F. W. Porter, and D. Weissman, “mRNA Vaccines — A New Era in Vaccinology,” Nature Reviews Drug Discovery17 (2018): 261.

[142] C. L. Lorentzen, J. B. Haanen, Ö. Met, and I. M. Svane, “Clinical Advances and Ongoing Trials of mRNA Vaccines for Cancer Treatment,” Lancet Oncology23 (2022): e450.

[143] B. R. Anderson, H. Muramatsu, S. R. Nallagatla, et al., “Incorporation of Pseudouridine Into mRNA Enhances Translation by Diminishing PKR Activation,” Nucleic Acids Research38 (2010): 5884.

[144] N. Chaudhary, D. Weissman, and K. A. Whitehead, “mRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation,” Nature Reviews Drug Discovery20 (2021): 817.

[145] K. A. Hajj and K. A. Whitehead, “Tools for Translation: Non-Viral Materials for Therapeutic mRNA Delivery,” Nature Reviews Materials2 (2017): 17056.

[146] R. Verbeke, M. J. Hogan, K. Loré, and N. Pardi, “Innate Immune Mechanisms of mRNA Vaccines,” Immunity55 (2022): 1993.

[147] M. Paranjpe and C. C. Müller-Goymann, “Nanoparticle-Mediated Pulmonary Drug Delivery: A Review,” International Journal of Molecular Sciences15 (2014): 5852.

[148] M. Radiom, M. Sarkis, O. Brookes, E. K. Oikonomou, A. Baeza-Squiban, and J. Berret, “Pulmonary Surfactant Inhibition of Nanoparticle Uptake by Alveolar Epithelial Cells,” Scientific Reports10 (2020): 19436.

[149] Z. Deng, Y. Rong, Y. Teng, et al., “Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase,” Molecular Therapy25 (2017): 1641.

[150] B. Wang, X. Zhuang, Z. Deng, et al., “Targeted Drug Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released From Grapefruit,” Molecular Therapy22 (2014): 522.

[151] M. A. C. Pomatto, C. Gai, F. Negro, et al., “Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine,” Pharmaceutics15 (2023): 974.

[152] S. H. Kim and Y. S. Jang, “The Development of Mucosal Vaccines for Both Mucosal and Systemic Immune Induction and the Roles Played by Adjuvants,” Clinical and Experimental Vaccine Research6 (2017): 15.

[153] J. M. Lee, M. Lee, E. Garon, et al., “Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-Cell Infiltration,” Clinical Cancer Research23 (2017): 4556.

[154] E. Tutunea-Fatan, M. Majumder, X. Xin, and P. K. Lala, “The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer-Induced Lymphangiogenesis,” Molecular Cancer14 (2015): 35.

[155] W. Zhao, G. Zhao, and B. Wang, “Revisiting GM-CSF as an Adjuvant for Therapeutic Vaccines,” Cellular & Molecular Immunology15 (2018): 187.

[156] P. Ji, W. Sun, S. Zhang, et al., “Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy,” Advanced Sciences10 (2023): e2301789.

[157] E. D. Pastuzyn, C. E. Day, R. B. Kearns, et al., “The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer,” Cell172 (2018): 275.

[158] D. Koeberl, A. Schulze, N. Sondheimer, et al., “Interim Analyses of a first-In-Human Phase 1/2 mRNA Trial for Propionic Acidaemia,” Nature628 (2024): 872-877.

[159] G. X. Cai, L. Lin, X. M. Zhai, et al., “A Plasma-Derived Extracellular Vesicle mRNA Classifier for the Detection of Breast Cancer,” Gland Surgery10 (2021): 2002.

[160] B. S. Cha, K. S. Park, and J. S. Park, “Signature mRNA Markers in Extracellular Vesicles for the Accurate Diagnosis of Colorectal Cancer,” Journal of Biological Engineering14 (2020): 4.

[161] H. Morio, Y. Sun, M. Harada, et al., “Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker,” Biological & Pharmaceutical Bulletin41 (2018): 445.

[162] T. Murakami, C. M. Yamamoto, T. Akino, et al., “Bladder Cancer Detection by Urinary Extracellular Vesicle mRNA Analysis,” Oncotarget9 (2018): 32810.

[163] P. P. Desai, K. Narra, J. D. James, H. P. Jones, A. K. Tripathi, and J. K. Vishwanatha, “BCombination of Small Extracellular Vesicle‑Derived Annexin A2 Protein and mRNA as a Potential Predictive Biomarker for Chemotherapy Responsiveness in Aggressive Triple‑Negative Breast Cancer,” Cancers15 (2018): 212.

[164] K. Otake, H. Kamiguchi, and Y. Hirozane, “Identification of Biomarkers for Amyotrophic Lateral Sclerosis by Comprehensive Analysis of Exosomal mRNAs in Human Cerebrospinal Fluid,” BMC Medical Genomics12 (2019): 7.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.